Vaccine-Associated Sarcomas in Cats: What a New Systematic Review Actually Tells Us.

By Steve Mehler, DVM, DACVS

For decades, few topics in veterinary medicine have generated more concern—and more misinformation—than vaccine-associated sarcomas (VAS) in cats.

Pet owners worry about causing cancer by vaccinating their cats. Veterinarians worry about balancing disease prevention with a rare but devastating complication.

A new systematic review and meta-analysis published in the Journal of Small Animal Practice provides one of the most comprehensive evaluations of the evidence to date.

The findings are reassuring in some ways, but they also remind us that vaccine-associated sarcomas remain a real, albeit uncommon, risk.

What Is a Vaccine-Associated Sarcoma?

A vaccine-associated sarcoma is an aggressive cancer that develops in tissues where an injection was previously administered.

Most are:

• Fibrosarcomas

• Malignant fibrous histiocytomas

• Other soft tissue sarcomas

These tumors are locally invasive, often requiring aggressive surgery and, in many cases, radiation therapy.

Fortunately, they are rare.

Why Do They Occur?

The exact cause remains uncertain.

The current theory is that chronic inflammation at an injection site may trigger malignant transformation of fibroblasts or myofibroblasts in genetically susceptible cats.

Importantly:

Vaccines are not the only injections associated with sarcoma formation.

Reports exist following:

• Long-acting corticosteroids

• Long-acting antibiotics

• Microchips

• Non-absorbable suture material

• Other injectable products

This suggests the underlying issue may be persistent inflammation rather than the vaccine itself.

What Did This Review Look At?

The authors performed a systematic review and meta-analysis of the veterinary literature.

They evaluated studies examining:

• Incidence of vaccine-associated sarcomas

• Risk factors

• Geographic variation

• Vaccine types

• Quality of evidence

Because VAS is uncommon, many available studies were retrospective.

The authors carefully assessed study quality before combining results.

How Common Are Vaccine-Associated Sarcomas?

The biggest takeaway is reassuring.

The review confirms that vaccine-associated sarcomas are rare.

Most estimates ranged between approximately:

1 to 36 cases per 10,000 vaccinated cats

depending on:

• Study design

• Population studied

• Case definitions

• Geographic region

While that range appears wide, the overall message is consistent:

The overwhelming majority of vaccinated cats will never develop one.

Which Vaccines Carry the Highest Risk?

Historically, the strongest association has been with:

• Rabies vaccines

• Feline leukemia virus (FeLV) vaccines

This does not necessarily mean these vaccines are inherently carcinogenic.

Instead, they have often been:

• Adjuvanted vaccines

• Administered repeatedly

• Given in consistent anatomical locations

Modern vaccine formulations have evolved considerably, and many practices now preferentially use non-adjuvanted products when appropriate.

Injection Site Matters

One of the most important advances over the past two decades has been changing where vaccines are administered.

Current recommendations favor:

• Rabies vaccine → right rear limb

• FeLV vaccine → left rear limb

• Distal limb administration whenever possible

Why?

Because if a sarcoma develops, complete surgical removal—or even limb amputation—offers the best chance for long-term control.

Tumors developing between the shoulder blades or over the pelvis are far more difficult to remove completely.

Should Cats Still Be Vaccinated?

Absolutely.

This review does not argue against vaccination.

Instead, it reinforces a principle veterinarians have embraced for years:

Vaccinate appropriately—not excessively.

Current best practice includes:

• Individual risk assessment

• Core vaccines only when indicated

• Avoiding unnecessary boosters

• Using current vaccination guidelines

• Choosing appropriate vaccine products

• Administering vaccines at recommended anatomical sites

The 3-2-1 Rule

Owners should monitor any injection-site swelling using the well-known 3-2-1 rule.

A lump should be evaluated if it:

• Persists for more than 3 months 

• Measures more than 2 cm in diameter 

• Continues growing 1 month after vaccination 

If any of these criteria are met, advanced imaging and biopsy are recommended rather than simply monitoring the mass.

Early diagnosis dramatically improves treatment options.

What Are the Limitations?

The authors point out several important limitations.

Many available studies:

• Were retrospective

• Used differing definitions of VAS

• Had inconsistent reporting

• Included varying vaccine formulations over decades

Because of this, determining the exact incidence remains challenging.

Nevertheless, the evidence consistently supports that vaccine-associated sarcomas are rare but real.

Bottom Line

This systematic review reinforces what most veterinary oncologists have believed for years:

• Vaccine-associated sarcomas are an uncommon complication of vaccination.

• The benefits of appropriate vaccination greatly outweigh this small risk for most cats.

• Modern vaccination protocols and injection-site recommendations have likely reduced the impact of these tumors.

• Monitoring injection sites and following the 3-2-1 rule allows earlier diagnosis and more successful treatment if a tumor does develop.

Like nearly every medical decision, vaccination is about balancing risk and benefit. This review reminds us that the goal isn't to avoid all risk—it's to minimize it while still protecting cats from serious, preventable infectious diseases.